Home » Health News » Currently Reading:

Four University Of Montreal Discoveries To Be Commercialized By Univalor And Cognitive Sensing Inc.

November 27, 2009 Health News 1 Comment

Cutting-edge technologies are about to enter the marketplace, thanks to a new partnership between Gestion Univalor, Limited Partnership (Univalor) and Cognitive Sensing Inc. (CSI), a privately owned technology company based in Montreal.

Univalor, which commercializes discoveries from the Université de Montréal and its affiliated institutions, and CSI have announced the signature of a license agreement giving CSI exclusive worldwide rights to develop, manufacture and market four scientifically proven products developed by Jocelyn Faubert, a professor at the Université de Montréal School of Optometry and CSI’s chief science officer.

Among the most anticipated products to emanate from Professor Faubert’s lab is a portable sports simulator that allows athletes to improve their game and reaction time. Another technology opens doors to the early detection, measurement and treatment of concussions and conditions such as Alzheimer’s and autism.

“We are impressed by the quality of the research generated by Prof. Jocelyn Faubert and his team. Technologies created in his lab present exciting market opportunities in the medical, sports and rejuvenation markets,” says Jean Castonguay, chief executive officer of CSI and a seasoned entrepreneur. “CSI has already entered into agreements with Industry leaders to validate the first applications of these technologies”.

Adds Marc Leroux, CEO of Univalor: “We are delighted to associate these Université de Montréal technologies with CSI and their experienced management team. We look forward to a lasting relationship.”

Patented technologies: Scientific validation of Prof. Faubert’s technologies was established in numerous peer-reviewed journals such as Brain and Psychological Science. His creations are currently being tested at several centers; the first are set for commercial validation in January 2010. Under the licensing agreement, CSI will provide financial support for patent protection in various territories in addition to other payments. The patented technologies include:

* MPI (Mild Perceptual Impairment Device): An apparatus to diagnose and monitor brain trauma, concussions, Alzheimer’s disease and other neurobiological conditions.

* 3D-MOT (3D Multiple Object Tracking): A device to enhance sports performance, as well as assess, train and improve perception in people of all ages.

* MSRS (Multisensory Stochastic Resonance Stimulation): A technology to improve sense and balance via auditory and visual stimulation.

* Noisy Bits: Software to improve image quality in standard displays and projectors by generating continuous luminance.

Source: Sylvain-Jacques Desjardins
University of Montreal

Go to Source

People who read this also read

Currently there is "1 comment" on this Article:

  1. Your article is amazing, I will forward it to my friends…
    Custom Essay | Buy Research Paper | Freelance Writing

ADS:

Related Articles:

Racial Disparity In Colon Cancer Survival Not Easily Explained

March 21, 2010

A new study by University of Alabama at Birmingham (UAB) researchers shows that body-mass index (BMI) and co-existing medical conditions (co-morbidity) do not explain the decreased survival observed among African-Americans compared to Caucasians who also have colon cancer. The study is published online Nov. 23 in Cancer, a journal of the American Cancer Society. (Source: Health News from Medical News Today) Go to Source… Continue reading

Pelosi Urged Obama To Not Cut Back On Health Care Plan

March 21, 2010

The New York Times recounts the steps Democrats took to regroup on the health overhaul legislation after losing their filibuster proof majority in the Senate after Massachusetts voters elected Republican Scott Brown in January. According to the Times account, House Speaker Nancy Pelosi helped steer President Barack Obama away from a more modest approach on health care. ‘“We’re in the majority,’ Ms. Pelosi told the president. ‘We’ll never have a better majority in your presidency in numbers than we’ve got right now. We can make this work,” the paper reported.”Now, in what could become a legislative Lazarus tale — or… Continue reading

Public Health receives grants to fight obesity, tobacco use

March 21, 2010

The U.S. Department of Health and Human Services and the U.S. Centers for Disease Control and Prevention announced today that Public Health – Seattle & King County has been awarded two highly-competitive federal stimulus grants totaling $25.5 million dollars over two years to address obesity and tobacco use, two of the leading contributors to premature illness, death and health care costs in the United States and locally.

“It’s a huge credit to our Public Health staff and partners that we were able to get such a competitive grant to improve our community’s health,” said King County Executive Dow Constantine. Over 600… Continue reading

Emisphere Technologies And Alchemia To Research An Oral Formulation Of Fondaparinux With Eligen(R) Technology

March 21, 2010

Emisphere Technologies, Inc. (OTCBB:EMIS) and Alchemia Ltd. (ASX:ACL) announced that they are joining efforts to develop an oral formulation of the anti-coagulant drug fondaparinux with Emisphere’s Eligen® Technology. Emisphere’s broad-based drug delivery platform, known as the Eligen® Technology, uses proprietary, synthetic carriers to enhance the oral bioavailability of a drug without altering its chemical form or biological activity. Fondaparinux, an anti-coagulant used for the prevention of deep vein thrombosis, is marketed in injectable form as Arixtra® by GlaxoSmithKline…

Go to Source… Continue reading

Emisphere Technologies And Alchemia To Research An Oral Formulation Of Fondaparinux With Eligen(R) Technology

March 21, 2010

Emisphere Technologies, Inc. (OTCBB:EMIS) and Alchemia Ltd. (ASX:ACL) announced that they are joining efforts to develop an oral formulation of the anti-coagulant drug fondaparinux with Emisphere’s Eligen® Technology. Emisphere’s broad-based drug delivery platform, known as the Eligen® Technology, uses proprietary, synthetic carriers to enhance the oral bioavailability of a drug without altering its chemical form or biological activity. Fondaparinux, an anti-coagulant used for the prevention of deep vein thrombosis, is marketed in injectable form as Arixtra® by GlaxoSmithKline…

Go to Source… Continue reading

Comment on this Article:







Security Code: